Search This Blog

Monday, July 26, 2021

Long path back to business as usual: UK coronavirus genome expert

 It is a long road back to business as usual from the COVID-19 pandemic, the head of Britain's coronavirus genome sequencing effort told Reuters, adding she was on alert for new mutations to the Delta variant that is sweeping the world.

Prime Minister Boris Johnson has ended England's coronavirus lockdown, saying Britain must cautiously learn to live with the virus, and that a quick vaccine rollout has allowed for a summer reopening.

Sharon Peacock, chair of the COVID-19 Genomics UK (COG-UK) consortium, said that the process of returning to normal would be slow, due to uneven vaccine rollouts globally.

"It's quite a long path to get back to business as usual," she told Reuters, adding that clear global surveillance for new variants and co-ordination on the best vaccine against what is coming up, as there is with flu, would be needed.

"I see that as quite a long journey. So it's not going to be one day that we wake up and say right we're going to live with COVID-19 and everything's okay. I think there's still a lot of groundwork to be done."

Britain has launched a New Variant Assessment Platform Programme to share its genomics expertise globally.

The variant of biggest concern at the moment is the Delta variant, which Peacock characterises as the "fittest and fastest variant yet".

Delta is highly transmissible and has also been shown to reduce the effectiveness of the first dose of COVID-19 vaccines, and could become even more troublesome.

"There's quite a lot of new mutations in the Delta variant, and so that's being watched very carefully. There's no reason at this point in time to be alarmed about that," she said.

"But we have to continue to watch for a particular sort of variant of a variant if you like, that is associated with, for example, even more spread... That's under constant monitoring at the moment."

https://news.trust.org/item/20210726100050-ymjwa

U.S. Will Not Lift Travel Restrictions, Citing Delta Variant

 The United States will not lift any existing travel restrictions "at this point" due to concerns over the highly transmissible COVID-19 Delta variant and the rising number of U.S. coronavirus cases, a White House official told Reuters.

The decision, which comes after a senior level White House meeting late Friday, means the long-running travel restrictions that have barred much of the world's population from the United States since 2020 will not be lifted in the short term.

"Given where we are today with the Delta variant, the United States will maintain existing travel restrictions at this point," the official told Reuters, citing the spread of the Delta variant in the United States and abroad.

"Driven by the Delta variant, cases are rising here at home, particularly among those who are unvaccinated and appear likely continue to increase in the weeks ahead."

The announcement almost certainly dooms any bid by U.S. airlines and the U.S. tourism industry to salvage summer travel by Europeans and others covered by the restrictions. Airlines have heavily lobbied the White House for months to lift the restrictions.

The United States currently bars most non-U.S. citizens who within the last 14 days have been in the United Kingdom, the 26 Schengen nations in Europe without border controls, Ireland, China, India, South Africa, Iran and Brazil.

The extraordinary U.S. travel restrictions were first imposed on China in January 2020 to address the spread of COVID-19 and other countries have been added since then -- most recently India in early May.

Last week, the U.S. Homeland Security Department said U.S. land borders with Canada and Mexico will remain closed to non-essential travel until at least Aug. 21 -- even as Canada said it would begin allowing in fully vaccinated American tourists starting Aug. 9.

Asked on July 15 at a joint appearance with German Chancellor Angela Merkel about when the United States would lift European travel restrictions, Biden said he would "be able to answer that question to you within the next several days — what is likely to happen."

Merkel said any decision to lift restrictions "has to be a sustainable decision. It is certainly not sensible to have to take it back after only a few days."

Since that press conference, U.S. cases have jumped.

U.S. Centers for Disease Control and Prevention (CDC) director Rochelle Walensky said Thursday the seven-day average of new cases in the United States was up 53% over the previous week. The Delta variant, which was first found in India, now comprises more than 80% of new cases nationwide and has been detected in more than 90 countries.

The White House official also cited the fact that last week, the CDC urged Americans to avoid travel to the United Kingdom, given a jump in cases.

But the official added: "The administration understands the importance of international travel and is united in wanting to reopen international travel in a safe and sustainable manner."

The restrictions have brought heavy criticism from people prevented from seeing loved ones.

White House spokeswoman Jen Psaki on Friday said international travel is "something we would all like to see — not just for tourism, but for families to be reunited."

But Psaki added "we rely on public health and medical advice on when we’re going to determine changes to be made."

The Biden administration has refused to offer any metrics that would trigger when it will unwind restrictions and has not disclosed if it will remove restrictions on individual countries or focus on enhancing individual traveler scrutiny.

Reuters reported last week the White House was discussing the potential of mandating COVID-19 vaccines for international visitors, but no decisions have been made, the sources said.

The Biden administration has also been talking to U.S. airlines in recent weeks about establishing international contact tracing for passengers before lifting travel restrictions.

The White House in early June launched interagency working groups with the European Union, Britain, Canada and Mexico to look at how eventually to lift travel and border restrictions.

In January, the CDC imposed mandatory COVID-19 testing requirements for nearly all international air travelers.

https://www.usnews.com/news/top-news/articles/2021-07-26/exclusive-us-will-not-lift-travel-restrictions-citing-delta-variant-official

Mixed AstraZeneca-Pfizer vaccine boosts antibody levels

 A new study found that antibody levels were boosted in people who got a shot of the AstraZeneca coronavirus vaccine and then a shot of the Pfizer vaccine, Reuters reported on Monday.

If the results hold, they could lead countries to combine the AstraZeneca vaccine with another vaccine to improve results. The AstraZeneca vaccine is in wide use in some countries, though the Pfizer and Moderna vaccines are much more widely used in the United States.

The study was conducted by the Korea Disease Control and Prevention Agency in South Korea and involved 499 medical workers.

In the study, 100 participants received one shot each of the two vaccines, while 200 others took two doses of the Pfizer shot and the remaining participants got two doses of the AstraZeneca shot.  

Those who received a shot of AstraZeneca and then a shot of the Pfizer vaccine saw their neutralizing antibody levels boosted six times compared to those who got the two AstraZeneca shorts, Reuters reported. 

Antibodies prevent a virus from replicating in cells. The results showed that the mixed AstraZeneca-Pfizer shots had the same effect of neutralizing antibodies for those who received the two Pfizer shots, according to Reuters. 

The new study comes as British scientists conducted their own study in June, showing that an AstraZeneca shot followed by Pfizer can produce the best T-cell and antibody response to the virus.

The delta variant of the COVID-19 virus has fueled the rise of cases throughout the world, with unvaccinated people being the vast majority of those contracting the virus. 

https://thehill.com/policy/healthcare/public-global-health/564829-mixed-astrazeneca-pfizer-vaccine-boosts-antibody

How the Delta Variant Upends Assumptions About Covid

 The Delta variant is the fastest, fittest and most formidable version of the coronavirus that causes COVID-19 the world has encountered, and it is upending assumptions about the disease even as nations loosen restrictions and open their economies, according to virologists and epidemiologists.

Vaccine protection remains very strong against severe disease and hospitalizations caused by any version of the coronavirus, and those most at risk are still the unvaccinated, according to interviews with 10 leading COVID-19 experts.

But evidence is mounting that the Delta variant, first identified in India, is capable of infecting fully vaccinated people at a greater rate than previous versions, and concerns have been raised that they may even spread the virus, these experts said.

As a result, targeted use of masks, social distancing and other measures may again be needed even in countries with broad vaccination campaigns, several of them said.

Israel recently reinstated mask-wearing requirements indoors and requires travelers to quarantine upon arrival.

U.S. officials are considering whether to revise mask guidance for the vaccinated. Los Angeles County, the most populous in the United States, is again requiring masks even among the vaccinated in indoor public spaces.

"The biggest risk to the world at the moment is simply Delta," said microbiologist Sharon Peacock, who runs Britain's efforts to sequence the genomes of coronavirus variants, calling it the "fittest and fastest variant yet."

Viruses constantly evolve through mutation, with new variants arising. Sometimes these are more dangerous than the original.

The major worry about the Delta variant is not that it makes people sicker, but that it spreads far more easily from person to person, increasing infections and hospitalizations among the unvaccinated.

    Public Health England said on Friday that of a total of 3,692 people hospitalized in Britain with the Delta variant, 58.3% were unvaccinated and 22.8% were fully vaccinated.

In Singapore, where Delta is the most common variant, government officials reported on Friday https://www.reuters.com/world/asia-pacific/vaccinated-people-singapore-make-up-three-quarters-recent-covid-19-cases-2021-07-23 that three quarters of its coronavirus cases occurred among vaccinated individuals, though none were severely ill.

Israeli health officials have said 60% of current hospitalized COVID-19 cases are in vaccinated people. Most of them are age 60 or older and often have underlying health problems.

In the United States, which has experienced more COVID-19 cases and deaths than any other country, the Delta variant represents about 83% of new infections. So far, unvaccinated people represent nearly 97% of severe cases.

Dr. Monica Gandhi, an infectious diseases doctor at the University of California, San Francisco, said many vaccinated people are "so disappointed" that they are not 100% protected from mild infections. But the fact that nearly all Americans hospitalized with COVID-19 right now are unvaccinated "is pretty astounding effectiveness," she said.

'TEACHING US A LESSON'

    "There is always the illusion that there is a magic bullet that will solve all our problems. The coronavirus is teaching us a lesson," said Nadav Davidovitch, director of Ben Gurion University's school of public health in Israel.

    The Pfizer Inc/BioNTech vaccine, one of the most effective against COVID-19 so far, appeared only 41% effective at halting symptomatic infections in Israel over the past month as the Delta variant spread, according to Israeli government data. Israeli experts said this information requires more analysis before conclusions can be drawn.

    "Protection for the individual is very strong; protection for infecting others is significantly lower," Davidovitch said.

    A study in China found that people infected with the Delta variant carry 1,000 times more virus in their noses compared with the original version first identified in Wuhan in 2019.

    "You may actually excrete more virus and that's why it's more transmissible. That's still being investigated," Peacock said.

Virologist Shane Crotty of the La Jolla Institute for Immunology in San Diego noted that Delta is 50% more infectious than the Alpha variant first detected in the UK.

"It's outcompeting all other viruses because it just spreads so much more efficiently," Crotty said.

    Genomics expert Eric Topol, director of the Scripps Research Translational Institute in La Jolla, California, noted that Delta infections have a shorter incubation period and a far higher amount of viral particles.

    "That's why the vaccines are going to be challenged. The people who are vaccinated have got to be especially careful. This is a tough one," Topol said.

    In the United States, the Delta variant has taken hold just as many Americans - vaccinated and not - have stopped wearing masks indoors.

    "It's a double whammy," Topol said. "The last thing you want is to loosen restrictions when you're confronting the most formidable version of the virus yet."

    The development of highly effective vaccines may have led many people to believe that once vaccinated, COVID-19 posed little threat to them.

    "When the vaccines were first developed, nobody was thinking that they were going to prevent infection," said Carlos del Rio, a professor of medicine and infectious disease epidemiology at Emory University in Atlanta. The aim was always to prevent severe disease and death, del Rio added.

The vaccines were so effective, however, that there were signs they also prevented transmission against prior coronavirus variants.

Sinovac COVID shot antibodies fade after about 6 months, booster helps

 Antibodies triggered by Sinovac Biotech's COVID-19 vaccine decline below a key threshold from around six months after a second dose for most recipients, although a third shot could have a strong boosting effect, according to a lab study.

Chinese researchers reported the findings from a study of blood samples from healthy adults aged between 18-59 in a paper published on Sunday, which has not been peer reviewed.

For participants receiving two doses, two or four weeks apart, only 16.9% and 35.2% respectively still had a level of neutralising antibodies above the threshold six months after the second dose, the paper said.

Those readings was based on data from two cohorts involving more than 50 participants each, while the study gave third doses to a total of 540 participants.

When participants in some cohorts were given a third dose, about six months after the second, neutralising antibody levels after a further 28 days had increased around 3-5 fold from the levels seen four weeks after the second dose, the study showed.

The study was conducted by researchers at disease control authorities in Jiangsu province, Sinovac, and other Chinese institutions.

Researchers cautioned the study did not test the antibodies' effect against more transmissible variants, and that further research was needed to assess antibody duration after a third shot. 

https://www.marketscreener.com/quote/stock/SINOVAC-BIOTECH-LTD-5714593/news/Sinovac-Biotech-Antibodies-from-Sinovac-s-COVID-19-shot-fade-after-about-6-months-booster-helps-35945154/

India to miss end-July vaccination target as Bharat Biotech lags

 

India will miss a target to administer over a half billion COVID-19 vaccine doses by the end of the month as Bharat Biotech - maker of its only approved homegrown shot - struggles to boost output, an analysis of government data showed on Monday.

India has undertaken one of the world's largest vaccination drives and has so far distributed some 430 million doses - more than any country except China, but less than many countries relative to its population.

The government said in May it would make 516 million shots available by the end of July. It wants to inoculate all its estimated 944 million adults by December.

To meet the July-end target, however, authorities will have to more than triple average daily vaccinations to 14 million doses. But that will not be possible, based on the latest supply projections for Bharat Biotech's Covaxin vaccine.

The government had been counting on deliveries of 60 million to 70 million Covaxin doses monthly from July or August.

But Bharat Biotech will only supply 25 million doses this month and 35 million in August as a new production line in the southern city of Bengaluru takes time to come online, Health Minister Mansukh Mandaviya told parliament last week.

Mandaviya added that the supply shortfall "would not affect our immunisation programme".

The health ministry did no immediately respond to a request for comment. Bharat Biotech declined to comment on its production.

The government is counting on 500 million doses of another vaccine from the Serum Institute of India (SII) and 400 million doses from Bharat Biotech between August and December for its vaccination campaign.

India's drug regulator controversially approved Bharat Biotech's Covaxin for emergency use in early January without efficacy data. But it has missed nearly all supply commitments to the government.

Immunisation efforts have also been hobbled by a delayed rollout of Russia's Sputnik V vaccine. And legal obstacles have prevented India from receiving U.S. donations of Moderna or Pfizer vaccines.

After halting exports in mid-April to meet domestic demand, SII meanwhile has nearly doubled output in the past three months.

Nearly 88% of all vaccine doses administered in India to date have been SII's Covishield shot, a version of the AstraZeneca vaccine.

The government expects the company to raise supplies of its Covishield vaccine to about 120 million doses in August from 100 million doses in June.

https://www.marketscreener.com/quote/stock/ASTRAZENECA-PLC-4000930/news/AstraZeneca-India-to-miss-end-July-vaccination-target-as-Bharat-Biotech-lags-35941559/

FDA ASKED PFIZER-BIONTECH, MODERNA TO INCLUDE 3,000 IN 5-TO-11 YEAR AGE GROUP STUDIES

https://www.marketscreener.com/news/latest/F-D-A-HAS-ASKED-PFIZER-BIONTECH-AND-MODERNA-TO-INCLUDE-3-000-CHILDREN-IN-THE-5-TO-11-YEAR-OLD-AGE-G--35946366/